Effects of candesartan on glomerular hemodynamics and permselectivity in patients with favorable renal allograft function

Transplantation

Volumn 79, Issue 6, 2005, Pages 710-715

  Hetzel, Gerd R ^a   Plum, Jörg ^a   Fusshöller, Andreas ^a   Voiculescu, Adina ^a   Grünberg, Wiebke ^a   Grabensee, Bernd ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Candesartan Nephroprotection; Proteinuria; Renal transplantation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CYCLOSPORIN A; DEXTRAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; EVALUATION; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; KIDNEY ALLOGRAFT; KIDNEY PLASMA FLOW; KIDNEY TRANSPLANTATION; KIDNEY VASCULAR RESISTANCE; MALE; PERFUSION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RECIPIENT; RENAL PROTECTION; SIDE EFFECT;

BENZIMIDAZOLES; BLOOD PRESSURE; CREATININE; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TETRAZOLES; TRANSPLANTATION, HOMOLOGOUS;

EID: 16244381125     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000155303.53547.20     Document Type: Article

References (28)

1. Feehally J, Harris KP, Bennett SE, Walls J. Is chronic renal transplant rejection a non-immunological phenomenon? Lancet 1986; 2: 486.
2. Hostetter TH. Chronic transplant rejection. Kidney Int 1994; 46: 266.
3. Mackenzie HS, Tullius SG, Heemann UW, et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 1994; 94: 2148.
4. Tullius SG, Hancock WW, Heemann U, et al. Reversibility of chronic renal allograft rejection: critical effect of time after transplantation suggests both host immune dependent and independent phases of progressive injury. Transplantation 1994; 58: 93.
5. Terasaki PI, Cecka JM, Gjertson DW, et al. High survival rates of kidney transplant from spousal and living unrelated donors. N Engl J Med 1995; 333: 333.
6. Mc Laren AJ, Jassem W, Gray DW, et al. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long term survival in cadaveric renal transplantation. Clin Transplant 1999; 13: 266.
7. Shoskes DA, Cecka JM: Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998; 66: 1697.
8. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53: 217.
9. Myers BD, Sibley R, Newton N, et al. The long-term course of ciclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590.
10. Zayas CF, Guasch A. Early glomerular dysfunction in human renal allografts. Kidney Int 2001; 60: 1938.
11. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73.
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851.
13. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 870.
14. Parving HH, Lehnert H, Brochner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 861.
15. Stigant CE, Cohen J, Vivera M, et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35: 58.
16. Del Castillo D, Campistol JM, Guirado L, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998; 68: S1 35.
17. Omoto K, Tanabe K, Tokumoto T, et al. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 2003; 76: 1170.
18. Plum J, Bünten B, Nemeth R, et al. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998; 9: 2223.
19. Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9: 1104.
20. Burnier M, Hagman M, Nussberger J, et al. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25: 602.
21. Gansevoort RT, de Zeeuw D, Shahinfar S, et al. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12: 37.
22. Morelli E, Loon N, Meyer T, et al. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76.
23. Remuzzi A, Perico N, Sangalli F, et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999; 276: F457.
24. Borchhardt K, Haas N, Yilmaz N, et al. Low dose angiotensin converting enzyme inhibition and glomerular permselectivity in renal transplant recipients. Kidney Int 1997; 52: 1622.
25. Deen WM, Bridges CR, Brenner BM, et al. Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. Am J Physiol 1985; 249: F374.
26. Remuzzi A, Battaglia C, Rossi L, et al. Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. Am J Physiol 1987; 253: F31.
27. Borchhardt KA, Yilmaz N, Haas M, et al. Renal function and glomerular permselectivity late after living related donor transplantation. Transplantation 1996; 62: 47.
28. Oberbauer R, Haas M, Regele H, et al. Glomerular permselectivity in proteinuric patients after kidney transplantation. J Clin Invest 1995; 96: 22.